Impaired Gastrointestinal Motility and Glycemic Control in Patients with Type 2 Diabetes
- Thu, 1/17/08 - 4:17am
- 0 Comments
- 3154 reads
Pages 36 - 45
CME ARTICLE
ACCREDITATION
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. Valid December 1, 2005- February 28, 2006. Estimated time: 1 hour
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following: Dr. Vinik has indicated that that he has been a consultant and/or speaker’s bureau member for Pfizer Inc., Genetech, Inc., Merck & CO., Inc., Eli Lilly and Company, Athena, Bristol-Myers Squibb Company, Knoll Pharmaceuticals, Novartis Pharmaceuticals Corporation, GlaxoSmith Kline Beecham, Boston Medical Technologies, NeuroMetrix, Inc., Guilford Pharmaceuticals Inc., R. W. Johnson Pharmaceutical Research Institute, Takeda Pharmaceutical Company Limited, TEVA Pharmaceutical Industries Ltd., AstraZeneca, Synergy Biosciences, Amgen Inc., Forest Laboratories, Inc., Sigma-Tau Research, Inc., Sankyo Co., Ltd., Ergomed Clinical Research, EMD Pharmaceuticals, NeurogesX, Inc., Sanofi-Synthelabo, Medco Health Solutions, Inc., Regeneron Pharmaceuticals, Inc., dLife, Health ABC, and Mitsubishi Pharma America, Inc. He has received grant support from GMP-Endotherapeutics, Inc., American Diabetes Association, U.S. Department of Housing and Urban Development, NASA, Eli Lilly and Company, Parke-Davis, ASTA Medica, SmithKline Beecham, National Institute on Aging, Lilly Research Laboratories, Lilly-Global Hypopituitary, Merck & CO., Inc., R. W. Johnson, National Institutes of Health, Takeda Pharmaceutical Company Limited, Commonwealth Health Research Board, Department of Health and Human Services, Juvenile Diabetes Research Foundation International, Pharmaceutical Product Development, Inc., Dyansys, Private Door Grants, AstraZeneca, Quintiles, Dainippon Pharmaceutical Co., Ltd., and Pliva. Dr. Vinik has indicated that his presentation will include information on unlabeled/unapproved products.
DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Educational Objectives
1. To understand the pathophysiology of gastroparesis
2. To understand the impact of diabetes in gastroparesis
3. To understand the impact of gastroparesis on type 2 diabetes
4.
REFERENCES 1. Department of Health and Human Services. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Atlanta, GA; 2003. Available at: cdc.gov/diabetes/pubs/pdf/ndfs_ 2003.pdf. Accessed September 8, 2005. 2. Pilotto A. Aging and upper gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004;18 suppl:73-81. 3. National Institute of Diabetes, Digestive and Kidney Diseases. Gastroparesis and diabetes. NIH Publication 04-4348, 2003. Available at: aboutgerd.org/gastroparesis.html. Accessed September 9, 2005. 4. Vinik A, Erbas T, Stansberry KB. Gastrointestinal, genitourinary and neurovascular disturbances in diabetes. Diabetes Rev 1999;7(4):358-378. 5. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553-1579. 6. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med 1983:98:378-384. 7. Horowitz M, Maddox AF, Wishart JM, et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991;18:229-234. 8. Lyrenas EB, Olsson EH, Arvidsson UC, et al. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 1997;20:413-418. 9. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15,000 adults. Arch Intern Med 2001;161:1989-1996. 10. Janatuinen E, Pikkarainen P, Laakso M, Pyorala K. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol 1993;28:427-432. 11. Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160:2808-2816. 12. Iber FL, Parveen S, Vandrunen M, et al. Relation of symptoms to impaired stomach, small bowel, and colon motility in long-standing diabetes. Dig Dis Sci 1993;38:45-50. 13. Ziegler D, Schadewaldt P, Pour Mirza A, et al. [13C]octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: Validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996;39:823-830. 14. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24:1264-1269. 15. Vinik A. Diabetic neuropathies. In: Kahn C, ed. Atlas of Clinical Endocrinology, vol. 2. Philadelphia: Current Medicine; 1999:164-174.16. Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43:2398-2404. 17. Abell T, Camilleri M, Hench V, et al. Gastric electromechanical function and gastric emptying in diabetic gastroparesis. Eur J Gastroenterol Hepatol 1991;3:163-167. 18. Koch KL, Stern RM, Vasey MW, et al. Neuroendocrine and gastric myoelectrical responses to illusory self-motion in humans. Am J Physiol 1990;258(2 pt 1):E304-E310. 19. Camilleri M. Advances in diabetic gastroparesis. Rev Gastroenterol Disord 2002;2:47-56. 20. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:675-680. 21. Oster-Jorgensen E, Pedersen SA, Larsen ML. The influence of induced hyperglycaemia on gastric emptying rate in healthy humans. Scand J Clin Lab Invest 1990;50:831-836. 22. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988;94: 739-744. Erratum in: Gastroenterology 1988;95(1):262. 23. Fraser R, Horowitz M, Dent J. Hyperglycaemia stimulates pyloric motility in normal subjects. Gut 1991;32:475-478. 24. Folwaczny C, Wawarta R, Otto B, et al. Gastric emptying of solid and liquid meals in healthy controls compared with long-term type-1 diabetes mellitus under optimal glucose control. Exp Clin Endocrinol Diabetes 2003;111:223-229. 25. Moore JG, Tweedy C, Christian PE, Datz FL. Effect of age on gastric emptying of liquid-solid meals in man. Dig Dis Sci 1983; 28:340-344. 26. Evans MA, Triggs EJ, Cheung M, et al. Gastric emptying rate in the elderly: Implications for drug therapy. J Am Geriatr Soc 1981;29:201-205. 27. Groop LC, Luzi L, DeFronzo RA, Melander A. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet 1989;2:129-130. 28. Hornbuckle K, Barnett JL. The diagnosis and work-up of the patient with gastroparesis. J Clin Gastroenterol 2000;30:117-124. 29. Glaser B, Zoghlin G, Pienta K, Vinik AI. Pancreatic polypeptide response to secretin in obesity: Effects of glucose intolerance. Horm Metab Res 1988;20:288-292. 30. McCallum RW, George SJ. Gastric dysmotility and gastroparesis. Curr Treat Options Gastroenterol 2001;4:179-191. 31. Reglan [prescribing information]. Baxter Healthcare Corporation: Deerfield, IL; 2003. 32. Motilium [package insert]. United Kingdom: Janssen-Cilag Ltd; 2005. 33. Petrakis IE, Vrachassotakis N, Sciacca V, et al. Hyperglycaemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol 1999;34:396-403. 34. Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 1992;102:823-828. 35. Smith DS, Williams CS, Ferris CD. Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction. Gastroenterol Clin North Am 2003;32:619-658. 36. Cuoco L, Montalto M, Jorizzo RA, et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology 2002;49:1582-1586. 37. Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002;97:1653-1660. 38. Bharucha AE, Camilleri M, Haydock S, et al. Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 2000;47:667-674. 39. Herranz R. Cholecystokinin antagonists: Pharmacological and therapeutic potential. Med Res Rev 2003;23:559-605. 40. Forster J, Sarosiek I, Lin Z, et al. Further experience with gastric stimulation to treat drug refractory gastroparesis. Am J Surg 2003;186:690-695. 41. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
